Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Blood (2012) 120 (21): 2636.

https://doi.org/10.1182/blood.V120.21.2636.2636

Published: 2012

Journal Articles

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

Teresa V. Halbsguth, Lucia Nogová, Horst Mueller, Michal Sieniawski, Dennis A. Eichenauer, Thomas Schober, Hiltrud Nisters-Backes, Peter Borchmann, Volker Diehl, Andreas Engert, Andreas Josting

Blood (2010) 116 (12): 2026–2032.

https://doi.org/10.1182/blood-2009-11-253211

Published: 2010

Journal Articles

“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”.

Karolin Behringer, Horst Mueller, Hans-Henning Flechtner, Corinne Brillant, Teresa Halbsguth, Thomas Schober, Hiltrud Nisters-Backes, Andreas Engert, MD, Peter Borchmann

Blood (2009) 114 (22): 896.

https://doi.org/10.1182/blood.V114.22.896.896

Published: 2009

Journal Articles

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Horst Mueller, Lucia Nogova, Dennis A Eichenauer, Teresa Halbsguth, Hiltrud Nisters-Backes, Thomas Schober, Hartmut Eimermacher, Peter Borchmann, Michael Fuchs, Andreas Engert, Andreas Josting

Blood (2008) 112 (11): 2600.

https://doi.org/10.1182/blood.V112.11.2600.2600

Published: 2008

Journal Articles

Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10–12 Trials of the German Hodgkin Study Group (GHSG).

Teresa Halbsguth, Horst Mueller, Hans-Henning Flechtner, Corinne Brillant, Karolin Behringer, Thomas Schober, Hiltrud Nisters-Backes, Andreas Engert, Peter Borchmann

Blood (2008) 112 (11): 1455.

https://doi.org/10.1182/blood.V112.11.1455.1455

Published: 2008

Journal Articles

Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease.

Andreas Josting, MD, Jeremy Franklin, PhD, Michal Sieniawski, MD, Beate Pfistner, PhD, Thomas Schober, Hildtrud Nisters-Backes, Andreas Engert, MD, Volker Diehl, MD

Blood (2005) 106 (11): 818.

https://doi.org/10.1182/blood.V106.11.818.818

Published: 2005

NARROW

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”.

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10–12 Trials of the German Hodgkin Study Group (GHSG).

Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease.

Email alerts

ASH Publications

American Society of Hematology

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”.

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10–12 Trials of the German Hodgkin Study Group (GHSG).

Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only